Omnicare bids for rival Pharmerica; AZ's dental unit sale gets regulatory OK;

@FiercePharma: Another cancer-drug rejection for NICE: Watchdog says AstraZeneca's Faslodex doesn't beat current therapy. News | Follow @FiercePharma

> Regulators approved AstraZeneca's ($AZN) sale of its Astra Tech dental unit to Dentsply International for $1.8 billion. Article

> Merck ($MRK) has tapped Richard DeLuca, Jr., to head up its animal health unit, succeeding Raul Kohan, who will retire. Report

> Lundbeck protested the use of its pentobarbital in a Virginia execution and promised that new distribution controls would keep the drug out of death-row prisons. Story

> Sangart's planned European headquarters and manufacturing plant in Cork, Ireland, will employ 250, twice as many people as originally announced. Item

> New evidence bolsters the idea that bisphosphonates such as Merck's ($MRK) Fosamax and Roche's Boniva might suppress development of cancer. Article

> GlaxoSmithKline ($GSK) bought 2 million shares for prices between 1238.5 pence and 1299 pence, as part of its ongoing buyback program. Story

Biotech News

@FierceBiotech: Stem cells from ear can create new cartilage. News | Follow @FierceBiotech

@JohnCFierce: Wondering if the dread "Dendreon effect" will alter any biotech's future marketing plans for cancer drugs. Leave it to the experts? | Follow @JohnCFierce

@RyanMFierce: U.S.'s brand as 'land of opportunity' is in jeopardy, I think. China biotech entrepreneur's quote says it all. Article | Follow @RyanMFierce

@MaureenFierce: Genzyme VP: Rare-disease drug developers in it for 'long-haul.' Story | Follow @MaureenFierce

> Bayer, Algeta shares spike as FDA fast-tracks blockbuster hopeful. Article

> Upstart biotech banks $13M for new eye drugs. News 

> Soured motavizumab deal triggers MedImmune suit against partner Abbott. Report

> 'Lilly effect' helps drive a life sciences boom in Indiana. Story 

Biotech Research News

> At last, a cause found for Lou Gehrig's disease. News

> Researchers build against body's natural defense against C. difficile. Article

> Stem cells from ears can create new cartilage. More

> Genzyme VP: Rare-disease drug developers in it for 'long haul.' Report

> A recipe for drug variation: Just add sugar. Story

> Stem cells to heart parts in 5 years, researchers say. Details

Manufacturing News

> WHO sends Panacea to remediation. More

> Meth makers to be foiled by jelly. Story

> Lilly, Genentech bolster QA functions. News

> Takeda parlays Baxter's vax methods into Japanese subsidies. Details

> Turbulence ahead for cancer drugs with Ben Venue exit. Report

> Sagent's vecuronium launch a hope against drug shortages. Article

And Finally... Duke University researchers identify a link beteween stress and DNA damage. Report

Suggested Articles

Eli Lilly has a pipeline stuffed with a host of assets and has decided it needs a new injectable drug and device plant to manufacture some of them.

After Clovis’ Rubraca snagged an FDA boost in prostate cancer last week, AZ and Merck’s rival Lynparza has matched it with a boost of its own.

An $8 billion jury verdict against Johnson & Johnson raised eyebrows back in October, but the judge has now slashed damages to just $6.8 million.